These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34066317)

  • 21. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
    Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
    Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Key Factors of a SARS-CoV-2 Vaccination Program: A Mathematical Modeling Approach.
    Martínez-Rodríguez D; Gonzalez-Parra G; Villanueva RJ
    Epidemiologia (Basel); 2021 Jun; 2(2):140-161. PubMed ID: 35141702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Offering onsite COVID-19 vaccination to high-risk obstetrical patients: initial findings.
    Hirshberg JS; Huysman BC; Oakes MC; Cater EB; Odibo AO; Raghuraman N; Kelly JC
    Am J Obstet Gynecol MFM; 2021 Nov; 3(6):100478. PubMed ID: 34481996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
    Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
    PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of mild and asymptomatic infections on COVID-19 vaccines performance: A modeling study.
    Aguiar M; Van-Dierdonck JB; Mar J; Stollenwerk N
    J Adv Res; 2022 Jul; 39():157-166. PubMed ID: 35777906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of age structure and vaccine prioritization on COVID-19 in West Africa.
    Taboe HB; Asare-Baah M; Yesmin A; Ngonghala CN
    Infect Dis Model; 2022 Dec; 7(4):709-727. PubMed ID: 36097593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lessons learned from COVID-19 vaccination in Indonesia: experiences, challenges, and opportunities.
    Arifin B; Anas T
    Hum Vaccin Immunother; 2021 Nov; 17(11):3898-3906. PubMed ID: 34613879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating the number of averted illnesses and deaths as a result of vaccination against an influenza pandemic in nine low- and middle-income countries.
    Lutz CS; Biggerstaff M; Rolfes MA; Lafond KE; Azziz-Baumgartner E; Porter RM; Reed C; Bresee JS
    Vaccine; 2021 Jul; 39(30):4219-4230. PubMed ID: 34119348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges and lessons from a school-based human papillomavirus (HPV) vaccination program for adolescent girls in a rural Nigerian community.
    Egbon M; Ojo T; Aliyu A; Bagudu ZS
    BMC Public Health; 2022 Aug; 22(1):1611. PubMed ID: 36002832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mathematical models for assessing vaccination scenarios in several provinces in Indonesia.
    Nuraini N; Sukandar KK; Hadisoemarto P; Susanto H; Hasan AI; Sumarti N
    Infect Dis Model; 2021; 6():1236-1258. PubMed ID: 34585032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Supporting the pandemic response and timely access to COVID-19 vaccines: a case for stronger priority setting and health system governance in Nigeria.
    Chukwu OA; Kapiriri L; Essue B
    Int J Pharm Pract; 2022 Jun; 30(3):284-287. PubMed ID: 35468198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 Vaccines in Indonesia: Knowledge, Attitudes, and Acceptance Among Dental Professionals.
    Theodorea CF; Widyarman AS; Dewanto I; Astoeti TE
    Front Med (Lausanne); 2021; 8():784002. PubMed ID: 34993213
    [No Abstract]   [Full Text] [Related]  

  • 35. Optimizing COVID-19 vaccination programs during vaccine shortages.
    Liu K; Lou Y
    Infect Dis Model; 2022 Mar; 7(1):286-298. PubMed ID: 35233475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use.
    Palache A; Rockman S; Taylor B; Akcay M; Billington JK; Barbosa P;
    Vaccine; 2021 Oct; 39(41):6081-6087. PubMed ID: 34521551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the impacts of COVID-19 vaccination programme's timing and speed on health benefits, cost-effectiveness, and relative affordability in 27 African countries.
    Liu Y; Procter SR; Pearson CAB; Montero AM; Torres-Rueda S; Asfaw E; Uzochukwu B; Drake T; Bergren E; Eggo RM; Ruiz F; Ndembi N; Nonvignon J; Jit M; Vassall A
    BMC Med; 2023 Mar; 21(1):85. PubMed ID: 36882868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disparities in global COVID-19 vaccination rates & allocation of resources to countries in need.
    Sen-Crowe B; McKenney M; Elkbuli A
    Ann Med Surg (Lond); 2021 Aug; 68():102620. PubMed ID: 34336193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of Priority Settings at the Start of COVID-19 Mass Vaccination on Subsequent Vaccine Uptake in Japan: One-Year Prospective Cohort Study.
    Hori D; Takahashi T; Ozaki A; Tabuchi T
    JMIR Public Health Surveill; 2023 Jul; 9():e42143. PubMed ID: 37235691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.